Feature Channels:

Pharmaceuticals

Add to Favorites | Subscribe | Share

Filters:

  • (Press "esc" to clear)

Medicine

Channels:

Bioinformatics, Genetics, Cancer, Pharmaceutical Science, Precision Medicine, CRISPR/Cas9

Gene Editing Technique Helps Find Cancer’s Weak Spots

synthetic_lethal_interactions_network_ideker.jpg

Genetic mutations that cause cancer also weaken cancer cells, allowing researchers to develop drugs that will selectively kill them. This is called “synthetic lethality” because the drug is only lethal to mutated (synthetic) cells. Researchers at UC San Diego School of Medicine and Jacobs School of Engineering developed a method to search for synthetic-lethal gene combinations. The technique, published March 20 in Nature Methods, uncovered 120 new opportunities for cancer drug development.

Medicine

Channels:

Researchers Discover Key to Drug Resistance in Common Breast Cancer Treatment

nettles_kendall.jpg

Scientists from the Florida campus of The Scripps Research Institute (TSRI), the University of California (UC), San Diego and the University of Illinois have found that two immune system molecules may be key to the development of drug resistance in estrogen-driven breast cancers.

Medicine

Channels:

pembrolizumab, Mesothelioma, immunotheraphy, Cancer

Pembrolizumab Shows Promise in Treatment of Mesothelioma

Pembrolizumab, an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study led by investigators from the Perelman School of Medicine at the University of Pennsylvania. The study, published this month in The Lancet Oncology, is the first to show a positive impact from checkpoint inhibitor immunotherapy drugs on this disease.

Science

Channels:

Chemistry/Physics/Materials Sciences (Biochemistry, Pharmaceutical Sciences); Biology (Biochemistry); Medicine/Health (Neurobiology, Pharmaceutical Science)

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 2-Apr-2017 5:00 AM EDT

Medicine

Channels:

Penn Medicine, Perelman School of Medicine at the University of Pennsylvania, Cardiovascular Medicine, Pulmonary Embolism

High-Risk Pulmonary Embolism Patients Often Go Without Most Effective Treatments

A typical intervention for PE patients includes anticoagulants in an effort to prevent migration of the blood clot, but the higher-risk PE population – about 30 percent of all PE patients – are potential candidates for catheter-directed thrombolysis (CDT) and systemic thrombolysis (ST), both of which employ “clot-busting” medications known as tissue plasminogen activator (tPA). However, in a new study presented today at the American College of Cardiology 66th Annual Scientific Session, researchers from the Perelman School of Medicine at the University of Pennsylvania have found that the utilization rates of these potentially life-saving medications are low, particularly in the sub-group of PE patients who are critically ill.

Medicine

Channels:

Blood Clots, Blood Thinners, Rivaroxaban, Venous Thromboembolism

New Blood Thinner Better at Preventing Recurrent Blood Clots Than Aspirin

VenousthromboembolismlegexamCreditTheOttawaHospital.jpg

Venous thromboembolism is a chronic disease, with risks of additional blood clots over a patient’s lifetime. However, many physicians and patients are deciding against long-term treatment with blood thinners because of concern about the risk of bleeding. Some are choosing aspirin instead because they consider it to be safer. This study has shown that the blood thinner rivaroxaban is as safe as aspirin, and more effective at preventing recurrence of life-threatening blood clots in the legs and lungs.

Medicine

Channels:

Appendectomy, Appendicitis, surgery alternative

Can Appendicitis Be Treated Solely with Medication?

appendicitis-treatment1.jpg

For 130 years, surgery has been the standard treatment for appendicitis — inflammation of the appendix, a short tube extending from the colon. After all, it’s best to remove an infected body part that is not essential to survival rather than risk a rupture that spews bacteria into the abdomen. Right? Maybe not. UCLA Dr.

Medicine

Channels:

Part D Plans, Medical Insurance, Penn Medicine, cancer drug costs, Out-of-Pocket Costs, Health Policy

Penn Researchers Find Patients’ Annual Financial Burden Under Medicare Part D Is “Too Much Too Soon”

A study released today by researchers at the Perelman School of Medicine at the University of Pennsylvania documents the patient out-of-pocket cost burden under Medicare prescription drug plans (known as Medicare Part D) and finds that despite having insurance, Medicare patients using specialty drugs paid thousands of dollars in out-of-pocket costs in a calendar year. Study authors also propose policy changes that would help patients better predict monthly bills for critical medications.

Medicine

Channels:

Anticoagulant, Stroke, Dialysis Patients

Reduced Dose of Warfarin Alternative May Help Prevent Strokes in Dialysis Patients

• In dialysis patients who took 2.5 mg of apixaban twice daily, blood concentrations of the drug were maintained at therapeutic levels.

Medicine

Channels:

Scripps Florida Scientists Develop New Drug Delivery Method for Cancer Therapy

rader_li_cropped.png

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a new drug delivery method that produces strong results in treating cancers in animal models, including some hard-to-treat solid and liquid tumors.







Chat now!